ISB News

ISB Gets $1.7M to Study Cancer Drug Resistance

Congratulations to the Sui Huang Lab at ISB which has received a five-year $1.7 million R01 award from the National Institutes of Health and National Institute for General Medical Sciences to study cancer sub-population dynamics to understand and develop drugs to inhibit lethal cancer-drug resistance. The project proposal states that the work will: “develop a quantitative and formal framework for describing the temporal evolution of cell phenotype distribution in a tumor cell population to address the unmet need to understand how heterogeneity and subpopulation dynamics of tumor cell populations affect drug response.”

Learn more:

Cancer Treatment: A Systems Approach

New Principle of Chemo-Resistance Sheds Light on Cancer Evasiveness

Biggest Family Tree of Human Cells May Help Develop Cell-Replacement Therapies

 


 

Related Articles

  • New Method to Detect, Analyze Rare T Cells Another Step Toward Personalized Cancer Vaccines

    Members of ISB’s Heath Lab and their collaborators have developed a way to sensitively detect and analyze neoantigen-specific T-cell populations from tumors and blood. This promising development may have implications for creating targeted, individual-specific cancer vaccines.

  • The Cancer Paradox

    ISB’s Dr. Sui Huang uses the theory of complex systems and applies it to cancer research. In this video Q&A, he discusses the cancer paradox and highlights the importance of understanding the mechanism of what cancer treatments can backfire in order to open a new avenue for therapy and treatments.

  • Dr. Wei Wei Awarded CARE Grant

    The Andy Hill Cancer Research Endowment (CARE) is a public-private partnership that supports cancer research in Washington state. CARE announced ISB Assistant Professor Dr. Wei Wei as a CARE Fund Distinguished Researcher and awarded him $500,000.

Show More Articles